Soluble Neprilysin　― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ―-Reference-Cited by-同舟云学术

Soluble Neprilysin　― Cardiac Function and Outcome in Hypertrophic Cardiomyopathy ―

Published:2019-06-10 Issue:6 Volume:1 Page:261-267
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Yoshihisa Akiomi¹²,Yokokawa Tetsuro¹³,Ichijo Yasuhiro¹,Kimishima Yusuke¹,Kanno Yuki¹,Misaka Tomofumi¹²,Sato Takamasa¹,Oikawa Masayoshi¹,Kobayashi Atsushi¹,Yamaki Takayoshi¹,Sugimoto Koichi¹³,Kunii Hiroyuki¹,Takeishi Yasuchika¹

Affiliation:

1. Department of Cardiovascular Medicine, Fukushima Medical University

2. Department of Advanced Cardiac Therapeutics, Fukushima Medical University

3. Department of Pulmonary Hypertension, Fukushima Medical University

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/1/6/1_CR-19-0034/_pdf

Reference34 articles.

1. 1. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733–2779.

2. 2. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58: e212–e260.

3. 3. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270–276.

4. 4. D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, Senni M. Neprilysin inhibition in heart failure: Mechanisms and substrates beyond modulating natriuretic peptides. Eur J Heart Fail 2017; 19: 710–717.

5. 5. Bayes-Genis A, Barallat J, Galan A, de Antonio M, Domingo M, Zamora E, et al. Multimarker strategy for heart failure prognostication. Value of neurohormonal biomarkers: Neprilysin vs NT-proBNP. Rev Esp Cardiol (Engl Ed) 2015; 68: 1075–1084.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of the literature on CD10: its function, clinical application, and prospects;Frontiers in Pharmacology;2024-02-08

2. Prognostic Role of Circulating LTBP-2 in Patients With Dilated Cardiomyopathy: A Novel Biomarker Reflecting Extracellular Matrix LTBP-2 Accumulation;Canadian Journal of Cardiology;2023-10

3. Relevance of Neutrophil Neprilysin in Heart Failure;Cells;2021-10-28